Altimmune, Inc. — Director's Dealing 2010

Nov 30, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2010-11-22

Reporting Person: PAPPAJOHN JOHN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-11-22	Common Stock	C	444044	$2.5416	Acquired	444044	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-11-22	10% Convertible Note	$2.5416	C		Disposed	2011-07-28	Common Stock (444044)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	911164	Direct

Footnotes

F1: The 10% Convertible Note (the "Note") reported herein was, and the underlying shares reported herein are, owned by the
Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of such Note and shares, and this report
shall not be deemed an admission that the reporting person was or is the beneficial owner of the Note or shares for purposes
of Section 13(d) or Section 16 of the Exchange Act or for any other purpose.

F2: The Note, including accrued interest thereon through 11/3/2010, was convertible into the Issuer's Common Stock at a price of
$2.541667 per share.

F3: Immediately.

F4: This Note, together with a Warrant, was received pursuant to a Note and Warrant Purchase Agreement dated as of July 24, 2009,
as amended on July 26, 2009 and July 28, 2009, by and among the Issuer and certain noteholders, all as more specifically
reported on Form 4 filed with the Securities & Exchange Commission on July 30, 2009.